Neuralgia, Postherpetic Clinical Trial
— MannitolPHNOfficial title:
Mannitol Cream in the Treatment of Post-herpeticNeuralgia;a Randomized Placebo-Controlled Crossover Pilot Study
Verified date | October 2018 |
Source | University of British Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
30% mannitol cream has shown its ability to reduce the activation of the Capsaicin (TRPV1) (Transient Receptor Potential Vanilloid 1) receptor, a likely cause of the pain of post-herpetic neuralgia (PHN). This randomized placebo-controlled crossover study compares PHN pain one week before, for one week on the randomly assigned mannitol versus placebo cream and, after a three day washout, for one week on the other cream. Following this crossover study, participants receive mannitol cream for three months. Pain levels will be checked to assess whether continued use of this cream significantly reduces the pain levels associated with PHN. If pain persists beyond 3 months, participants will be offered mannitol and menthol cream for one month following which their pain levels will be checked.
Status | Completed |
Enrollment | 20 |
Est. completion date | April 30, 2017 |
Est. primary completion date | April 29, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria 1. - Suffering from post-herpetic neuralgia on the trunk or the extremities for at least three months. 2. - Maximum daily pain score greater than or equal to 5/10. 3. - Having failed to improve with at least one neuropathic pain medication. 4- Able and willing to fill a fluid survey NRS pain scale and a medication intake questionnaire daily, preferably online but on paper, if unable, for the first 24 days of the study, then once a month for three months.. 5 - Preferably have access to someone who can apply cream to their back if they have pain in the back and cannot reach the area. 6 - If that is not possible, ability to apply the cream to their own back, using an applicator which will be supplied. Exclusion Criteria: 1. Allergies to any of the ingredients of the cream 2. Open lesions or abrasions on the skin where the cream will be applied 3. Using corticosteroids 4. Unwilling to stop using other topical products (creams or patches) for the treatment of post-herpetic neuralgia 5. Pregnant, breast-feeding or not using birth control 6. Suffering from severe chronic pain from a cause other than post-herpetic neuralgia |
Country | Name | City | State |
---|---|---|---|
Canada | Dr. Helene Bertrand Inc. | North Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia |
Canada,
Bertrand H, Kyriazis M, Reeves KD, Lyftogt J, Rabago D. Topical Mannitol Reduces Capsaicin-Induced Pain: Results of a Pilot-Level, Double-Blind, Randomized Controlled Trial. PM R. 2015 Nov;7(11):1111-7. doi: 10.1016/j.pmrj.2015.05.002. Epub 2015 May 12. — View Citation
Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc. 2015 Apr;90(4):532-45. doi: 10.1016/j.mayocp.2015.01.018. Review. — View Citation
Shannon HJ, Anderson J, Damle JS. Evidence for interventional procedures as an adjunct therapy in the treatment of shingles pain. Adv Skin Wound Care. 2012 Jun;25(6):276-84; quiz 285-6. doi: 10.1097/01.ASW.0000415345.22307.f3. Review. — View Citation
Szolcsányi J, Sándor Z. Multisteric TRPV1 nocisensor: a target for analgesics. Trends Pharmacol Sci. 2012 Dec;33(12):646-55. doi: 10.1016/j.tips.2012.09.002. Epub 2012 Oct 12. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in worst NRS (Numerical Rating Scale) pain score | In the last 24 hours, how bad was your pain at its worst? No pain 0 1 2 3 4 5 6 7 8 9 10 Worst pain imaginable | Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months | |
Primary | Change in average NRS (Numerical Rating Scale) pain score | In the last 24 hours, how bad was your pain on average? No pain 0 1 2 3 4 5 6 7 8 9 10 Worst pain imaginable | Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months | |
Secondary | Change in Pain medication intake | Number of pills taken for pain in one day. Will decrease as the pain intensity decreases. Write the number of tablets that you took: 1. Tylenol/acetaminophen______, 2. Anti-inflammatory medication like Advil/ibuprofen, naproxen, diclofenac, Voltaren, Aleve______, 3. Tylenol or ASA (acetylsalicylic acid) plus narcotic like Tylenol 3, or 292 or Tramacet (acetaminophen/tramadol) ______, 4. Narcotic like morphine, hydromorphone/dilaudid, fentanyl, Demerol, tramadol______, 5. Cannabis, marijuana, or pot______, The total in each category will be added to calculate the total number of tablets taken in 24 hours. | Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3,months | |
Secondary | Change in Alcohol intake | Number of alcoholic drinks in one day. May decrease as the pain intensity decreases. Write down the total number of alcoholic drinks you had in the last 24 hours:how many glasses of wine ______ glasses of hard liquor______ bottles of beer______. The total number of glasses will be recorded. | Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months | |
Secondary | Change in questions from the brief pain inventory score | The total from the following questions will be recorded to measure how much their pain is interfering with their lives: Circle one number. In the last 24 hours, how much has your pain interfered with your: General activity:, Mood: Walking ability: Normal work: (includes both work outside the home and housework) Relations with other people: Sleep: Enjoyment of life: Each of these will be scored as follows: does not interfere 0 1 2 3 4 5 6 7 8 9 10 completely interferes. The scores added up. This sum should decrease as the pain decreases. |
Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months | |
Secondary | Change in PHQ-9 (Personal health questionnaire, 9 questions) Score | Patients will fill the PHQ - 9 score. http://phqscreeners.com/pdfs/02_PHQ-9/English.pdf The sum of the answers from this questionnaire, which is used to measure the degree of depression, may decrease as the pain intensity decreases. | Before each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months | |
Secondary | Change in Method of cream application | Patients will describe whether they use cling wrap (4), gentle applicator (3) or rubbing in gently (2) or vigourous rubbing (1) | when each cream is first applied, 7 days later, and for mannitol cream 1,2 and 3 months | |
Secondary | Change in effect and side effects of the cream | How many times did you apply the cream today?_______ Circle one number. How bad was your pain?.. Before you applied the cream? NRS 0-10 1hour after you applied the cream? NRS 0-10 Did the cream relieve your pain? No ? if Yes ? in how many minutes?____ For how many hours was your pain relieved?____ Did you experience a side effect from the cream? No ? if Yes ? What was it?_________________ Any comments?_______________________ | Daily for the 14 days, of the crossover study, then at 1,2 and 3 months | |
Secondary | Satisfaction from cream use | How satisfied were you with the use of this cream? Not at all satisfied 0 1 2 3 4 5 6 7 8 9 10 extremely satisfied | Three months after use of mannitol cream was started. | |
Secondary | Change in pain score from mannitol cream use to mannitol and menthol cream use | Maximum pain score after 3 months of mannitol cream use compared to maximum pain score after one month of mannitol and menthol cream use | 1st measurement Three months after use of mannitol cream was started 2nd measurement one month after mannitol and menthol cream started |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00964990 -
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)
|
Phase 2 | |
Completed |
NCT00394901 -
A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
|
Phase 3 | |
Completed |
NCT01252160 -
Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage
|
Phase 4 | |
Completed |
NCT00377598 -
Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia
|
Phase 2/Phase 3 | |
Completed |
NCT00160667 -
A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
|
Phase 2 | |
Terminated |
NCT00245544 -
Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)
|
Phase 2 | |
Completed |
NCT00335933 -
Safety and Efficacy of Gabapentin in Postherpetic Neuralgia
|
Phase 3 | |
Completed |
NCT00617461 -
A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
|
Phase 2 | |
Withdrawn |
NCT02426411 -
Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN
|
Phase 2 | |
Completed |
NCT01129531 -
A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia
|
Phase 2 | |
Completed |
NCT00674687 -
A Study Of The Efficacy Of Gabapentin In Neuropathic Pain Patients As Measured By Quantitative Sensory Testing
|
N/A | |
Terminated |
NCT01678924 -
A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia
|
Phase 2 | |
Completed |
NCT00424372 -
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia
|
Phase 3 | |
Completed |
NCT00619476 -
A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)
|
Phase 2 | |
Terminated |
NCT00295776 -
Lamictal in the Treatment of Post-Herpetic Neuralgia
|
Phase 2/Phase 3 | |
Completed |
NCT00570310 -
Neuropathic Pain Syndrome Patient Study (MK-0000-072)
|
Phase 1 | |
Terminated |
NCT00282763 -
A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)
|
Phase 2 | |
Completed |
NCT00568321 -
RN624 For Pain Of Post-Herpetic Neuralgia
|
Phase 2 | |
Not yet recruiting |
NCT01102101 -
Effect of Opioids in Neuropathic Pain in Postherpetic Patients
|
Phase 3 | |
Completed |
NCT00614705 -
PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia
|
Phase 2 |